DNDN News Alert Dendreon Corp (DNDN) 0.13 12/16/2014 22:55:1

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Dendreon Corp (DNDN) 0.13 $DNDN

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs
at The Street - Tue Dec 16, 10:20AM CST
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
VRTX: 110.86 (-2.02), MYGN: 33.02 (-0.41), DNDN: 0.13 (-0.02), CTIC: 2.21 (-0.01), REGN: 396.13 (-4.88), CELG: 110.09 (-1.79)

Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 4.94 (-0.02), DNDN: 0.13 (-0.02), RTRX: 11.12 (+0.56), CYTR: 2.16 (+0.01), RPRX: 8.21 (+0.13), GALE: 1.53 (-0.10), AEGR: 20.21 (-0.07)

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions
at The Street - Sat Dec 06, 12:00PM CST
A new form of cancer immunotherapy known as CAR-T promises to radically change the way certain blood cancers are treated.
BLUE: 85.87 (-0.33), KITE: 52.49 (-1.41), DNDN: 0.13 (-0.02), NVS: 91.65 (+0.01), CELG: 110.09 (-1.79)

A New Combined Approach to Cancer Immunotherapy is Needed
ACCESSWIRE - Mon Dec 01, 11:35AM CST
NEW YORK, NY / ACCESSWIRE / December 1, 2014 / With the recent bankruptcy of Dendreon Corporation (NASDAQ NDN) due to disappointing sales of its flagship Provenge prostate cancer vaccine, the future of cancer immunotherapy just got a bit cloudier. While Provenge itself will survive, Dendreon may end up going private in a debt restructuring deal.
DNDN: 0.13 (-0.02), AMGN: 159.44 (-0.16), LLY: 69.26 (-0.41), BMY: 57.69 (-0.86)

Northwest Biotherapeutics' DCVax-L: A Reimbursement Perspective
Ryan Pawell - at Seeking Alpha - Sun Nov 23, 3:41AM CST

NWBO: 4.94 (-0.02), DNDN: 0.13 (-0.02)

Most active Nasdaq-traded stocks
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 17.25 (+0.40), GILD: 100.46 (-2.70), FB: 74.69 (-2.30), DNDN: 0.13 (-0.02), MSFT: 45.16 (-1.51), INTC: 35.56 (-0.36), GRPN: 6.83 (-0.18), AAPL: 106.75 (-1.47), CSCO: 26.58 (-0.10)

Will Patterson Companies (PDCO) Surprise Earnings in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:40PM CST
Patterson Companies (PDCO) had a mixed first quarter in which revenues beat the Zacks Consensus Estimate while adjusted earnings fell shy.
KR: 61.50 (-0.03), DNDN: 0.13 (-0.02), BBY: 35.77 (-1.14), PDCO: 47.12 (-0.02)

Market Maker Surveillance Report. DNDN, YHOO, CRDC, FNMAS, SLTD, BABA, Highest Net Sell Volume and Negative Price Friction For Thursday, November 13th 2014
M2 - Fri Nov 14, 3:02AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4759 companies with "abnormal" market making, 1814 companies with positive Friction Factors and 3114 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Thursday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Dendreon Corp (NASDAQ NDN), Yahoo! Inc (NASDAQ:YHOO), Cardica Inc (NASDAQ:CRDC), Federal National Mortgage Association Fannie Mae (OTC:FNMAS), Solar3D Inc (OTC:SLTD), (NYSE:BABA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
YHOO: 48.85 (-0.97), DNDN: 0.13 (-0.02), CRDC: 0.63 (+0.02), BABA: 105.77 (+1.07)

Political Intelligence Rules Urged On D.C. Insiders
at Investor's Business Daily - Thu Nov 13, 5:54PM CST
The term "political intelligence" may sound like an oxymoron, but it can make a difference in investors' portfolios and has drawn the eye of legislators and investigators. Political intelligence is the business of people providing information about...
DNDN: 0.13 (-0.02), UNH: 95.85 (-2.42), AET: 85.64 (-1.03), HUM: 141.15 (-1.93)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 110.86 (-2.02), GILD: 100.46 (-2.70), ACHN: 12.92 (+0.20), DNDN: 0.13 (-0.02), AMGN: 159.44 (-0.16), ABBV: 65.25 (-0.37), REGN: 396.13 (-4.88)

Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
PR Newswire - Wed Nov 12, 7:45AM CST
EarningForecast.com has issued six earnings forecast research reports with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Zynga (NASDAQ:ZNGA), Gilead Sciences (NASDAQ:GILD), Dendreon (NASDAQ NDN), and Juniper (NYSE:JNPR).
GILD: 100.46 (-2.70), DNDN: 0.13 (-0.02), ZNGA: 2.32 (-0.12), AAPL: 106.75 (-1.47), JNPR: 21.37 (+0.11), BABA: 105.77 (+1.07)

Nasdaq stocks posting largest volume increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HEAR: 3.48 (-0.11), LSBK: 13.45 (+0.09), VSAR: 19.17 (+0.11), SANW: 3.68 (+0.16), URRE: 1.92 (-0.03), EDUC: 4.59 (-0.01), MCEP: 6.16 (+0.66), CYAN: 5.93 (-0.01), DNDN: 0.13 (-0.02), SUMR: 2.76 (+0.01), CRTN: 4.13 (+0.10)

Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 102.50 (-1.58), AGN: 205.75 (-3.26), JNJ: 102.76 (-1.20), DNDN: 0.13 (-0.02)

Update: Dendreon Bankruptcy
Alexander Maxwell - at Seeking Alpha - Tue Nov 11, 12:55PM CST

DNDN: 0.13 (-0.02)


Clarification: Dendreon-Chapter 11 Filing story
By The Associated Press - AP - Tue Nov 11, 12:43PM CST
In a story Nov. 10, The Associated Press reported that Bank of New York Mellon was listed as the largest creditor in a Chapter 11 bankruptcy court filing involving the drugmaker Dendreon Corp. BNY Mellon administers $620 million in notes for investors; it does not own them.
DNDN: 0.13 (-0.02)

Bankruptcies, Breakouts, and Busts; What's Happening in Biotech?
ACCESSWIRE - Tue Nov 11, 10:34AM CST
CORAL GABLES, FL / ACCESSWIRE / November 11, 2014 / From prostate cancer drugs to stem-cell therapy, the biotech industry seems to encompass a variety of unique and innovative companies. According to market research firm IBISWorld, the global revenue of the Biotech industry is nearly $300 billion. Statista reports that more that $50Billion of US biopharmaceutical goods are exported and the industry is on pace to grow at a compounded annual rate of nearly 11%. IBIS notes that many small companies, alongside a few industry giants in pharmaceutical, chemical and agricultural firms, populate the global biotech industry. There is also a lower level of market share concentration as noted by IBISWorld estimates that the top four industry players will account for less than 28% of the industry's revenue in 2014. With so much potential there are certainly companies in the market, which have progressed to the next level and others that have mismanaged their businesses into bankruptcy.
DNDN: 0.13 (-0.02)

Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST

VRTX: 110.86 (-2.02), GILD: 100.46 (-2.70), MRK: 56.80 (-0.15), DNDN: 0.13 (-0.02), AZN: 69.56 (-0.18), TEVA: 55.15 (-0.47), ABBV: 65.25 (-0.37), GSK: 41.92 (+0.62), BMY: 57.69 (-0.86), NVS: 91.65 (+0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Honda Prelude’s Hybrid Return Tests a Narrow Niche

Updated Category News Views 0

A low-slung coupe showing up in Newfoundland is not exactly a volume-sales thunderclap, and that is precisely why the 2027 Honda Prelude deserves a closer look. Steele Honda in St. John’s is presenting the hybrid two-door as a fresh choice for buyers who want something livelier than the usual practical commuter. For Honda, and for investors watching Honda Motor Co....

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 54

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 73

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 82

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 77

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
The Estate Bets Over $1 Billion on Luxury Longevity

Updated Category News Views 108

A billion-dollar wellness promise just wandered into the condominium market. The Estate by sbe says its first three branded residential developments carry combined real estate value above $1 billion and encompass more than 500 units. That is not pocket change, and it is certainly not a routine hotel-brand licensing exercise dressed up with scented candles and a cold...

Continue Reading
Envision’s COP31 Pitch Hinges on Grid Execution, Not Targets

Updated Category News Views 69

A 2,500 GW traffic jam is a rotten place to park climate ambition. Envision Energy used COP31 in Antalya to make the more useful point: clean-power targets mean very little if grids cannot connect, balance and dispatch the electricity. Kane Xu’s message was not another round of flag-waving promises. It was an argument that the constraint has shifted from wanting...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 22

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
Replit Bets on Trusted Creators to Sell AI Agents at Work

Updated Category News Views 201

Forty-five creators may sound like a marketing footnote, but Replit is aiming at a real enterprise bottleneck: people do not buy grand AI slogans; they buy proof that a messy internal problem can actually get fixed. Its newly launched Replit & Co. program puts business and technology creators in front of that problem, with product access, demonstrations and direct contact...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 75

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading

Top 5 Most Recently Viewed Articles

New York Times: Strong Growth Ahead with Innovative Strategies

Updated Category News Views 103

New York Times Positioned for Future Profit Growth Recently, Deutsche Bank has taken a significant step by initiating coverage on shares of the New York Times (NYSE:NYT) with a promising Buy rating and a price target of $65.00. Their analysis highlights the media company's innovative digital-first subscription model and strong fundamentals as major drivers of growth and...

Continue Reading
Maximizing Opportunities in Today's Commercial Insurance Market

Updated Category News Views 151

Understanding the Current U.S. Commercial Insurance Landscape In today’s economic climate, U.S. commercial insurance buyers are navigating one of the most advantageous periods witnessed in recent years. Despite this promising environment, the looming uncertainties affecting the economy pose challenges that require careful consideration from both buyers and insurers...

Continue Reading
Understanding the Market Activity of Dowlais Group Plc Deals

Updated Category News Views 179

Key Information About Dowlais Group Plc This disclosure pertains to an exempt principal trader engaged in client-serving transactions involving Dowlais Group Plc, providing essential insights into the movements and transactions related to its shares. Notable Dealings by the Exempt Principal Trader As highlighted, important dealings regarding the ordinary shares of Dowlais...

Continue Reading
Golden State Dermatology's Smart Expansion into Los Altos

Updated Category News Views 20

Golden State Dermatology Welcomes Todd Anhalt The Bay Area’s dermatology landscape just got an intriguing development. Todd Anhalt, a veteran dermatologist with a track record as long as a roll of duct tape, has teamed up with Golden State Dermatology (GSD). This Los Altos partnership isn't just about slapping a new name on a door—it's a strategic move to bolster...

Continue Reading
Unlocking Tesla's Future: AI, Innovation, and Growth Strategies

Updated Category News Views 117

Tesla got itself into a tight spot back in the day, trading around 40% lower than its peak. Folks were already getting antsy about where the stock was heading—had to keep an eye on those quarterly delivery numbers. The car side of things? Over 80% of projected revenues for FY24 came straight from that segment, so if it tanked, so did the whole show. Tesla's Valuation...

Continue Reading